SAN FRANCISCO, CA--(Marketwired - October 05, 2017) - A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.
Included in this article is: DURECT Corp. (
In an Oct. 2 press release, DURECT Corp. announced "a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior Plc, whereby DURECT has assigned certain of its U.S. patent rights to Indivior." The deal, according to the press release, "may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia."
DURECT received $12.5 million upfront in the agreement, "with the potential for an additional $5 million based on a regulatory milestone," according to the release. Indivior Plc is a $3.5 billion market cap company.
Continue reading this article: Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURES:
The following company mentioned in this article is a billboard sponsor of Streetwise Reports: DURECT Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
Please see the end of the article for the complete disclosures: Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia
Contact Information:
Contact Information:
Carrie Beal Amaro
Associate Publisher